Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …

Background Homologous recombination deficiency (HRD) is a phenotype that is
characterized by the inability of a cell to effectively repair DNA double-strand breaks using …

The recognition of homologous recombination deficiency (HRD) as a frequent feature of
high-grade serous ovarian cancer (HGSOC) has transformed treatment paradigms. Poly …

Poly (ADP-ribose) polymerases (PARP) are proteins responsible for DNA damage detection
and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for …

In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR
inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to …

DNA double-strand breaks foster tumorigenesis and cell death. Two distinct mechanisms
can be activated by the cell for DNA repair: the accurate mechanism of homologous …

The genome of each cell in the human body is constantly under assault from a plethora of
exogenous and endogenous processes that can damage DNA. If not successfully repaired …

Background The search for biomarkers to evaluate ovarian cancer (OC) homologous
recombination (HR) function and predict the response to therapy is an urgent clinical need to …

Background TP53 mutation and hypoxia play an essential role in cancer progression.
However, the metabolic reprogramming and tumor microenvironment (TME) heterogeneity …